PFE vs VKTX

Pfizer Inc. remains a mature, large-cap pharmaceutical company with limited potential for the requested 10x growth within 3-5 years, which would require a market cap exceeding $1.4 trillion. While Q1 2026 results showed revenue of $14.45B and adjusted EPS of $0.75, both beating estimates, YoY revenue growth was modest at +5.4% and adjusted EPS declined -18%. Strategic legal wins for VYNDAQEL and C...

Viking Therapeutics maintains strong 10x growth potential, with its lead asset VK2735 (a dual GLP-1/GIP agonist) continuing to show compelling clinical promise in the lucrative metabolic disorder market. Recent additional positive Phase 2 data for the oral formulation, showing up to 12.2% weight loss, reinforces its potential as a best-in-class option and strengthens its competitive position. Whil...